JAK1 selective inhibitors for the treatment of spondyloarthropathies

Journal article

Abstract:: As our understanding of the pathogenesis of spondyloarthropathies improves, focus has turned to the role janus kinase (JAK) mediated signal transduction and inhibiting its actions as a therapeutic mechanism. Small molecule inhibitors of JAK exist, with variable selectivity for the different JAK isoforms. Less selective JAK inhibitors have variable efficacy and safety profiles, prompting the investigation of selective JAK1 inhibition. In this review, we summarise the current phase 2 and 3 clinical trial data, evaluating the use of JAK1 selective inhibitors in the treatment of spondyloarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Selective JAK1 inhibition offers a promising therapeutic approach, however further longer-term trials are needed to fully establish their efficacy and safety at higher doses, and their use in the greater continuum of spondyloarthropathies.

Files:: VoR_JPEWhite_LCCoates_May2021_OUP_Rheumatology_60_S2_keaa815.pdf

(Preview, Version of record, 180.0KB, Terms of use)

Language:: English
Keywords:: psoriatic arthritis

ankylosing spondylitis

axial spondyloarthritis

spondyloarthropathies

treatment

management

selective janus kinase inhibitors

FFR
Pubs id:: 1140320
Local pid:: pubs:1140320
Deposit date:: 2020-11-03

Copyright holder:: JPE White and LC Coates.
Rights statement:: © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [email protected]

If you are the owner of this record, you can report an update to it here: Report update to this record